Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center

被引:10
|
作者
Chung, Lindsey Yoojin [1 ,2 ]
Kang, Eungu [2 ]
Nam, Hyo-Kyoung [2 ]
Rhie, Young-Jun [2 ]
Lee, Kee-Hyoung [2 ]
机构
[1] Hanyang Univ, Myongji Hosp, Dept Pediat, Coll Med, Goyang, South Korea
[2] Korea Univ, Dept Pediat, Coll Med, 73 Goryeodae Ro, Seoul 02841, South Korea
关键词
Central Precocious Puberty; Triptorelin Pamoate; Gonadotropin-releasing Hormone Analogue; Korea; GNRH ANALOG; 11.25; MG; LEUPROLIDE; CHILDREN; THERAPY; SAMPLE; TRIAL; LH;
D O I
10.3346/jkms.2021.36.e219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Triptorelin depot is largely used to treat central precocious puberty (CPP) in children, and a 3-month depot has been introduced. However, data about the 3-month gonadotropin-releasing hormone use for treatment of CPP in Korean girls are not available. This study was conducted to compare the efficacy of a triptorelin 11.25 mg 3-month depot with that of a 3.75 mg 1-month depot in suppressing pubertal development for the treatment of CPP. Methods: A retrospective study, including 106 girls with CPP treated with triptorelin, was conducted. Fifty patients were treated with a triptorelin 3-month depot, and 56 were treated with a triptorelin 1-month depot. Serum luteinizing hormone (LH), follicle-stimulating hormone, and estradiol levels were analysed every 6 months after the visit. The height and bone age of each patient was evaluated at the beginning of treatment, after 6 months, and one year after therapy. Results: The baseline characteristics of the girls treated with a 3-month depot were similar to those of the girls treated with a 1-month depot. A suppressed levels of LH to the triptorelin injection (serum LH < 2.5 IU/L) at 6 months was seen in 90.0% and 98.2% of the girls treated with the 3-month and 1-month depots, respectively (P = 0.160). After 1 year of treatment, a suppressed levels of LH was seen in 93.5% and 100% of the girls treated with the 3-month and 1-month depots, respectively (P = 0.226). Height velocity showed no significant difference between the two groups. Degree of bone age advancement decreased from 1.22 +/- 0.07 and 1.22 +/- 0.08 years at baseline (P = 0.914) to 1.16 +/- 0.07 and 1.17 +/- 0.08 in the girls treated with the 3-month and 1-month depots after 1 year, respectively (P = 0.481). Conclusion: This study showed that the efficacy of long-acting triptorelin 3-month was comparable to 1-month depot regarding hormonal suppression and inhibition of bone maturation. The triptorelin 11.25 mg 3-month depot is an effective treatment for girls with CPP.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 35 条
  • [21] Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer - Discussion
    Jocham
    Tunn
    Teillac
    UROLOGIA INTERNATIONALIS, 1998, 60 : 16 - 17
  • [22] Pharmacokinetic and Exposure–Response Analyses of Leuprolide Following Administration of Leuprolide Acetate 3-Month Depot Formulations to Children with Central Precocious Puberty
    Nael M. Mostafa
    Balakrishna Hosmane
    Lois M. Larsen
    Kristof Chwalisz
    Yi-Lin Chiu
    Rajendra S. Pradhan
    Clinical Drug Investigation, 2014, 34 : 441 - 448
  • [23] EXTRAPOLATION OF THE PHARMACOKINETICS AND EFFICACY OF LEUPROLIDE ACETATE FOR CENTRAL PRECOCIOUS PUBERTY TO A NEW 6 MONTH DEPOT FORMULATION.
    Dufek, M.
    Mensing, S.
    Mostafa, N. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S30 - S31
  • [24] A 12-month, open-label, single-arm, phase 3 trial of the efficacy and safety of triptorelin 3-month formulation in Chinese children with central precocious puberty (CPP)
    Luo, Xiaoping
    Zhang, Cai
    Yang, Yu
    Xu, Xu
    Cheng, Xinran
    Wei, Haiyan
    Wang, Lanying
    Huang, Frank
    Cabri, Patrick
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 389 - 390
  • [25] Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study
    Luo, Xiaoping
    Zhang, Cai
    Yang, Yu
    Xu, Xu
    Cheng, Xinran
    Wei, Haiyan
    Wang, Lanying
    Huang, Frank
    Shi, Xiaofeng
    Cabri, Patrick
    ADVANCES IN THERAPY, 2023, 40 (10) : 4574 - 4588
  • [26] Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study
    Xiaoping Luo
    Cai Zhang
    Yu Yang
    Xu Xu
    Xinran Cheng
    Haiyan Wei
    Lanying Wang
    Frank Huang
    Xiaofeng Shi
    Patrick Cabri
    Advances in Therapy, 2023, 40 : 4574 - 4588
  • [27] Pharmacokinetic and Exposure-Response Analyses of Leuprolide Following Administration of Leuprolide Acetate 3-Month Depot Formulations to Children with Central Precocious Puberty
    Mostafa, Nael M.
    Hosmane, Balakrishna
    Larsen, Lois M.
    Chwalisz, Kristof
    Chiu, Yi-Lin
    Pradhan, Rajendra S.
    CLINICAL DRUG INVESTIGATION, 2014, 34 (07) : 441 - 448
  • [28] Practical Considerations for the Treatment of Central Precocious Puberty with a 3-Month Leuprolide Acetate Formulation
    Lee, Peter
    Luce, Margaret
    Bacher, H. Peter
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [29] Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty
    Isaac, H.
    Patel, L.
    Meyer, S.
    Hall, C. M.
    Cusick, C.
    Price, D. A.
    Clayton, P. E.
    HORMONE RESEARCH, 2007, 68 (04) : 157 - 163
  • [30] OUTCOMES OF GIRLS WITH IDIOPATHIC CENTRAL PRECOCIOUS PUBERTY TREATED WITH 1-AND 3-MONTH GONADOTROPIN-RELEASING HORMONE ANALOG FORMULATIONS
    Ramos, Carolina O.
    Silva, Marina C.
    Salles, Priscila
    Mendonca, Berenice B.
    Latronico, Ana Claudia
    Brito, Vinicius N.
    HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 543 - 544